ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.64
0.12%
US Tech 100
19,416.00
0.07%
S&P 500
5,487.03
0.25%
US Dollar vs CAD
1.37215
0.06%
Bitcoin
65,060.53
-2.14%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Altamira Therapeutics Ltd (CYTO)

  7. Altamira Therapeutics Ltd (CYTO) News

CYTO

Altamira Therapeutics (CYTO)

Altamira Therapeutics Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CYTO
DateTimeSourceHeadlineSymbolCompany
05/28/20249:31AMGlobeNewswire Inc.Altamira Therapeutics Provides Business UpdateNASDAQ:CYTOAltamira Therapeutics Ltd
05/23/20247:47AMGlobeNewswire Inc.Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy JournalNASDAQ:CYTOAltamira Therapeutics Ltd
05/16/20243:15PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
05/01/20247:47AMGlobeNewswire Inc.Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and InflammationNASDAQ:CYTOAltamira Therapeutics Ltd
04/24/20247:47AMGlobeNewswire Inc.Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed JournalNASDAQ:CYTOAltamira Therapeutics Ltd
04/10/20247:00AMGlobeNewswire Inc.Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial ResultsNASDAQ:CYTOAltamira Therapeutics Ltd
04/04/20247:45AMGlobeNewswire Inc.Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024NASDAQ:CYTOAltamira Therapeutics Ltd
03/25/20247:47AMGlobeNewswire Inc.Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA VaccinesNASDAQ:CYTOAltamira Therapeutics Ltd
02/07/20247:47AMGlobeNewswire Inc.Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed JournalNASDAQ:CYTOAltamira Therapeutics Ltd
01/24/20247:47AMGlobeNewswire Inc.Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer TreatmentNASDAQ:CYTOAltamira Therapeutics Ltd
01/22/20244:02PMEdgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:CYTOAltamira Therapeutics Ltd
01/21/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CYTOAltamira Therapeutics Ltd
01/19/20243:45PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
01/19/20243:40PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CYTOAltamira Therapeutics Ltd
01/19/20243:30PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
01/08/20244:02PMEdgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:CYTOAltamira Therapeutics Ltd
01/08/20247:47AMGlobeNewswire Inc.Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics SummitNASDAQ:CYTOAltamira Therapeutics Ltd
12/29/20237:47AMGlobeNewswire Inc.Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:CYTOAltamira Therapeutics Ltd
12/11/20237:01AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
12/11/20237:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
12/11/20237:00AMGlobeNewswire Inc.Altamira Therapeutics Provides Investor and Business UpdateNASDAQ:CYTOAltamira Therapeutics Ltd
12/08/20238:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
12/05/202311:54AMGlobeNewswire Inc.Altamira Therapeutics to Host Investor & Business Update Call on December 11thNASDAQ:CYTOAltamira Therapeutics Ltd
11/29/20239:20AMGlobeNewswire Inc.Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity RequirementNASDAQ:CYTOAltamira Therapeutics Ltd
11/22/20233:30PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
11/21/20237:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
11/17/20238:04AMGlobeNewswire Inc.Altamira Therapeutics Announces Partial Spin-Off of Bentrio® BusinessNASDAQ:CYTOAltamira Therapeutics Ltd
11/10/20237:47AMGlobeNewswire Inc.Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal BetahistineNASDAQ:CYTOAltamira Therapeutics Ltd
10/31/20233:30PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
10/04/20238:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
 Showing the most relevant articles for your search:NASDAQ:CYTO

Your Recent History

BIT
UC8HRY
Unicredit Bank
BIT
P20TC7
NLBNPIT20TC7 20240621 3.1
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved